BACKGROUND: An invasive treatment strategy improves outcome in patients with non-ST-elevation acute coronary syndrome at moderate to high risk. We hypothesized that the circulating level of growth differentiation factor 15 (GDF-15) may improve risk stratification. METHODS AND RESULTS: The Fast Revascularization during InStability in Coronary artery disease II (FRISC-II) trial randomized patients with non-ST-elevation acute coronary syndrome to an invasive or conservative strategy with a follow-up for 2 years. GDF-15 and other biomarkers were determined on admission in 2079 patients. GDF-15 was moderately elevated (between 1200 and 1800 ng/L) in 770 patients (37.0%), and highly elevated (>1800 ng/L) in 493 patients (23.7%). Elevated levels of GDF-15 independently predicted the risk of the composite end point of death or recurrent myocardial infarction in the conservative group (P=0.016) but not in the invasive group. A significant interaction existed between the GDF-15 level on admission and the effect of treatment strategy on the composite end point. The occurrence of the composite end point was reduced by the invasive strategy at GDF-15 levels >1800 ng/L (hazard ratio, 0.49; 95% confidence interval, 0.33 to 0.73; P=0.001), between 1200 and 1800 ng/L (hazard ratio, 0.68; 95% confidence interval, 0.46 to 1.00; P=0.048), but not <1200 ng/L (hazard ratio, 1.06; 95% confidence interval, 0.68 to 1.65; P=0.81). Patients with ST-segment depression or a troponin T level >0.01 microg/L with a GDF-15 level <1200ng/L did not benefit from the invasive strategy. CONCLUSIONS:GDF-15 is a potential tool for risk stratification and therapeutic decision making in patients with non-ST-elevation acute coronary syndrome as initially diagnosed by ECG and troponin levels. A prospective randomized trial is needed to validate these findings.
RCT Entities:
BACKGROUND: An invasive treatment strategy improves outcome in patients with non-ST-elevation acute coronary syndrome at moderate to high risk. We hypothesized that the circulating level of growth differentiation factor 15 (GDF-15) may improve risk stratification. METHODS AND RESULTS: The Fast Revascularization during InStability in Coronary artery disease II (FRISC-II) trial randomized patients with non-ST-elevation acute coronary syndrome to an invasive or conservative strategy with a follow-up for 2 years. GDF-15 and other biomarkers were determined on admission in 2079 patients. GDF-15 was moderately elevated (between 1200 and 1800 ng/L) in 770 patients (37.0%), and highly elevated (>1800 ng/L) in 493 patients (23.7%). Elevated levels of GDF-15 independently predicted the risk of the composite end point of death or recurrent myocardial infarction in the conservative group (P=0.016) but not in the invasive group. A significant interaction existed between the GDF-15 level on admission and the effect of treatment strategy on the composite end point. The occurrence of the composite end point was reduced by the invasive strategy at GDF-15 levels >1800 ng/L (hazard ratio, 0.49; 95% confidence interval, 0.33 to 0.73; P=0.001), between 1200 and 1800 ng/L (hazard ratio, 0.68; 95% confidence interval, 0.46 to 1.00; P=0.048), but not <1200 ng/L (hazard ratio, 1.06; 95% confidence interval, 0.68 to 1.65; P=0.81). Patients with ST-segment depression or a troponin T level >0.01 microg/L with a GDF-15 level <1200 ng/L did not benefit from the invasive strategy. CONCLUSIONS:GDF-15 is a potential tool for risk stratification and therapeutic decision making in patients with non-ST-elevation acute coronary syndrome as initially diagnosed by ECG and troponin levels. A prospective randomized trial is needed to validate these findings.
Authors: Tibor Kempf; Alexander Zarbock; Christian Widera; Stefan Butz; Anika Stadtmann; Jan Rossaint; Matteo Bolomini-Vittori; Mortimer Korf-Klingebiel; L Christian Napp; Birte Hansen; Anna Kanwischer; Udo Bavendiek; Gernot Beutel; Martin Hapke; Martin G Sauer; Carlo Laudanna; Nancy Hogg; Dietmar Vestweber; Kai C Wollert Journal: Nat Med Date: 2011-04-24 Impact factor: 53.440
Authors: Anand Rohatgi; Parag Patel; Sandeep R Das; Colby R Ayers; Amit Khera; Abelardo Martinez-Rumayor; Jarett D Berry; Darren K McGuire; James A de Lemos Journal: Clin Chem Date: 2011-11-07 Impact factor: 8.327
Authors: Abhinav Sharma; Susanna R Stevens; Joseph Lucas; Mona Fiuzat; Kirkwood F Adams; David J Whellan; Mark P Donahue; Dalane W Kitzman; Ileana L Piña; Faiez Zannad; William E Kraus; Christopher M O'Connor; G Michael Felker Journal: JACC Heart Fail Date: 2017-10 Impact factor: 12.035
Authors: Paul W X Foley; Berthold Stegemann; Kelvin Ng; Sud Ramachandran; Anthony Proudler; Michael P Frenneaux; Leong L Ng; Francisco Leyva Journal: Eur Heart J Date: 2009-08-07 Impact factor: 29.983